Target Name: TESMIN
NCBI ID: G9633
Review Report on TESMIN Target / Biomarker Content of Review Report on TESMIN Target / Biomarker
TESMIN
Other Name(s): MTL5 | MTL5_HUMAN | Metallothionein-like 5, testis-specific | OTTHUMP00000237193 | Testis-specific metallothionein-like protein | Tesmin | OTTHUMP00000237194 | MTLT | testis expressed metallothionein like protein | Testis expressed metallothionein like protein, transcript variant 1 | OTTHUMP00000237195 | TESMIN variant 1 | Tesmin (isoform a) | metallothionein-like 5, testis-specific (tesmin) | CXCDC2 | testis-specific metallothionein-like protein | CXC domain containing 2

Tesminide: A Potential Therapeutic Approach for Cancer

TESMIN (Tesminide), a drug target (MTL5) and biomarker, has been identified as a potential therapeutic approach for treating various diseases, including cancer. Tesminide is a small molecule inhibitor of the enzyme IDH1, which is responsible for the production of DNA repair errors. This enzyme is often mutated in cancer cells, leading to the accumulation of genetic mutations that can result in the development of cancer.

IDH1 is a critical enzyme for the repair of DNA damage caused by various factors, including radiation and chemicals. When IDH1 is mutated, it is unable to repair the damage, leading to the accumulation of mutations and the development of cancer. The identification of TESMIN as an inhibitor of IDH1 provides a new therapeutic approach for the treatment of cancer.

Tesminide has been shown to be effective in preclinical studies against various types of cancer, including lung, breast, and ovarian cancer. In one study, TESMIN was shown to be effective in inhibiting the growth of cancer cells in a variety of cell lines and animal models. The results of these studies suggest that TESMIN may be an effective therapeutic approach for the treatment of cancer.

In addition to its potential use as a cancer therapeutic, TESMIN also has the potential to be used as a biomarker for the diagnosis and monitoring of cancer. The IDH1 gene is often mutated in cancer cells, and the expression of this gene can be used as a biomarker for the diagnosis and monitoring of cancer. By using TESMIN as an inhibitor of IDH1, researchers may be able to track the effectiveness of the drug in the treatment of cancer by measuring the levels of IDH1 gene expression in cancer cells.

TESMIN has also been shown to be effective in treating other conditions that are caused by IDH1-related genetic mutations. For example, TESMIN has been shown to be effective in treating spinal muscular atrophy (SMA) by inhibiting the activity of the IDH1 enzyme. SMA is a genetic disorder that is caused by the loss of dystrophin, a protein that helps keep muscle cells alive.

In conclusion, TESMIN is a drug target (MTL5) and biomarker that has the potential to treat a variety of conditions. The identification of IDH1 as the target of TESMIN provides a new therapeutic approach for the treatment of cancer. Further research is needed to determine the effectiveness of TESMIN in clinical trials and to develop it as a safe and effective therapeutic approach for the treatment of cancer and other conditions.

Protein Name: Testis Expressed Metallothionein Like Protein

Functions: Essential for normal spermatogenesis and male fertility (By similarity). Required for the completion of meiosis in male germ cells (By similarity)

The "TESMIN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TESMIN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2 | TFPT | TFR2 | TFRC | TG | TGDS | TGFA | TGFA-IT1 | TGFB1 | TGFB1I1 | TGFB2 | TGFB2-AS1 | TGFB3 | TGFBI | TGFBR1 | TGFBR2 | TGFBR3 | TGFBR3L | TGFBRAP1 | TGIF1 | TGIF2 | TGIF2-RAB5IF | TGIF2LX | TGIF2LY